We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
-7.72%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$157M
AUM Growth
+$31.7M
Cap. Flow
+$45.5M
Cap. Flow %
28.95%
Top 10 Hldgs %
45.06%
Holding
108
New
39
Increased
16
Reduced
23
Closed
22

Top Buys

Rank Stock Value
1
V icon
Visa
V
+$8.9M
2
MA icon
Mastercard
MA
+$8.7M
3
FISV
Fiserv Inc
FISV
+$8.43M
4
PYPL icon
PayPal
PYPL
+$6.75M
5
FIS icon
Fidelity National Information Services
FIS
+$4.01M

Top Sells

Rank Stock Value
1
XLNX
Xilinx Inc
XLNX
+$5.13M
2
INFO
IHS Markit Ltd. Common Shares
INFO
+$4.35M
3
NUAN
Nuance Communications, Inc.
NUAN
+$3.59M
4
CONE
CyrusOne Inc Common Stock
CONE
+$3.47M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$1.99M

Sector Composition

Rank Sector Weight
1 Healthcare 44.39%
2 Technology 25.46%
3 Financials 19.54%
4 Consumer Discretionary 2.88%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
76
Madrigal Pharmaceuticals
MDGL
$12.4B
$444K 0.28%
+4,525
New +$382K
SWTX
77
DELISTED
SpringWorks Therapeutics
SWTX
$438K 0.28%
7,755
-10,115
-57% -$579K
MORF
78
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$438K 0.28%
10,917
-12,834
-54% -$537K
BMRN icon
79
BioMarin Pharmaceuticals
BMRN
$13.5B
$431K 0.27%
+5,593
New +$468K
NBP
80
NovaBridge Biosciences American Depositary Shares
NBP
$213M
$413K 0.26%
+25,402
New +$651K
VTGN icon
81
VistaGen Therapeutics
VTGN
$11.9M
$392K 0.25%
10,529
-8,705
-45% -$380K
ONC
82
BeOne Medicines Ltd
ONC
$40.6B
$378K 0.24%
2,002
-578
-22% -$123K
IMGN
83
DELISTED
Immunogen Inc
IMGN
$370K 0.24%
+77,694
New +$430K
GRTS
84
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$364K 0.23%
88,318
-25,434
-22% -$135K
ANAB icon
85
AnaptysBio
ANAB
$1.71B
$346K 0.22%
+13,998
New +$424K
VERV
86
DELISTED
Verve Therapeutics
VERV
$321K 0.2%
14,073
-4,709
-25% -$135K
AVIR icon
87
Atea Pharmaceuticals
AVIR
$404M
– –
-20,659
Closed -$185K
BPMC
88
DELISTED
Blueprint Medicines
BPMC
– –
-13,843
Closed -$1.48M
FULC icon
89
Fulcrum Therapeutics
FULC
$282M
– –
-89,963
Closed -$1.59M
IVVD icon
90
Invivyd
IVVD
$203M
– –
-65,068
Closed -$472K
MGNX icon
91
MacroGenics
MGNX
$249M
– –
-54,012
Closed -$867K
NRIX icon
92
Nurix Therapeutics
NRIX
$2.69B
– –
-18,796
Closed -$544K
OCUL icon
93
Ocular Therapeutix
OCUL
$2.14B
– –
-58,965
Closed -$411K
OLMA icon
94
Olema Pharmaceuticals
OLMA
$911M
– –
-50,942
Closed -$477K
PMVP icon
95
PMV Pharmaceuticals
PMVP
$69.3M
– –
-39,777
Closed -$919K
RGNX icon
96
Regenxbio
RGNX
$703M
– –
-29,753
Closed -$973K
SNDX icon
97
Syndax Pharmaceuticals
SNDX
$1.81B
– –
-38,347
Closed -$839K
SPRY icon
98
ARS Pharmaceuticals
SPRY
$591M
– –
-22,434
Closed -$149K
STTK icon
99
Shattuck Labs
STTK
$686M
– –
-89,220
Closed -$759K
TIL icon
100
Instil Bio
TIL
$50.8M
– –
-2,845
Closed -$974K
1 2 3
4
5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q1 2022 Portfolio in Review

As of Q1 2022, HighVista Strategies held 108 positions worth $157M, up 25% from $126M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

HighVista Strategies deployed $45.5M of net new capital in Q1 2022, opening 39 new positions and adding to 16 existing holdings. Its largest new stake was Visa: 41,135 shares worth $9.12M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 53% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $1.05M trimmed.

  • HighVista Strategies's largest Q1 2022 buy was Visa: 41,135 shares worth $9.12M.
  • HighVista Strategies added most to Protagonist Therapeutics in Q1 2022, an estimated $1.72M increase.
  • HighVista Strategies's biggest Q1 2022 reduction was Xenon Pharmaceuticals, cutting an estimated $1.05M.
  • HighVista Strategies fully exited Xilinx Inc in Q1 2022, selling an estimated $5.13M.
  • HighVista Strategies's ten largest holdings make up 45% of its $157M portfolio in Q1 2022.
  • HighVista Strategies opened 39 new positions and closed 22 in Q1 2022.
  • HighVista Strategies's portfolio value rose 25% quarter-over-quarter to $157M.

Based on HighVista Strategies's 13F filing for Q1 2022, filed 16 May 2022.